Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Isis and Alnylam in RNAi deal

Executive Summary

In a product swap agreement involving double-stranded RNAi patents, Isis Pharmaceuticals licensed Alnylam Pharmaceuticals (therapeutics based on RNAi) rights to its patent estate relating to antisense mechanisms and oligonucleotide chemistry. In turn, Alnylam provided Isis with rights to its patent applications. The companies plan to develop and commercialize RNAi therapeutics.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Product or Technology Swap
    • Includes Contract
    • Intra-Biotech Deal

Related Companies